AU2011314074B2 - ND2 peptides and methods of treating neurological disease - Google Patents

ND2 peptides and methods of treating neurological disease Download PDF

Info

Publication number
AU2011314074B2
AU2011314074B2 AU2011314074A AU2011314074A AU2011314074B2 AU 2011314074 B2 AU2011314074 B2 AU 2011314074B2 AU 2011314074 A AU2011314074 A AU 2011314074A AU 2011314074 A AU2011314074 A AU 2011314074A AU 2011314074 B2 AU2011314074 B2 AU 2011314074B2
Authority
AU
Australia
Prior art keywords
peptide
pain
src
tat
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011314074A
Other languages
English (en)
Other versions
AU2011314074A1 (en
Inventor
Johathan David Garman
Rongwen Li
Michael Tymianski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NoNO Inc
Original Assignee
NoNO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NoNO Inc filed Critical NoNO Inc
Publication of AU2011314074A1 publication Critical patent/AU2011314074A1/en
Application granted granted Critical
Publication of AU2011314074B2 publication Critical patent/AU2011314074B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/05—Oxidoreductases acting on NADH or NADPH (1.6) with a quinone or similar compound as acceptor (1.6.5)
    • C12Y106/05003—NADH dehydrogenase (ubiquinone) (1.6.5.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2011314074A 2010-09-28 2011-09-28 ND2 peptides and methods of treating neurological disease Ceased AU2011314074B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38743910P 2010-09-28 2010-09-28
US61/387,439 2010-09-28
PCT/US2011/053764 WO2012050921A2 (en) 2010-09-28 2011-09-28 Nd2 peptides and methods of treating neurological disease

Publications (2)

Publication Number Publication Date
AU2011314074A1 AU2011314074A1 (en) 2013-05-09
AU2011314074B2 true AU2011314074B2 (en) 2015-11-12

Family

ID=45938878

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011314074A Ceased AU2011314074B2 (en) 2010-09-28 2011-09-28 ND2 peptides and methods of treating neurological disease

Country Status (15)

Country Link
US (1) US9073976B2 (enExample)
EP (1) EP2621945B1 (enExample)
JP (1) JP6073230B2 (enExample)
KR (1) KR101893473B1 (enExample)
CN (1) CN103282379B (enExample)
AU (1) AU2011314074B2 (enExample)
BR (1) BR112013007557A2 (enExample)
CA (1) CA2812948C (enExample)
DK (1) DK2621945T3 (enExample)
IL (1) IL225464B (enExample)
MX (1) MX343366B (enExample)
RU (1) RU2607033C2 (enExample)
SG (1) SG189104A1 (enExample)
UA (1) UA114592C2 (enExample)
WO (1) WO2012050921A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA123820C2 (uk) * 2014-05-28 2021-06-09 Ноно Інк. Хлоридна сіль пептиду tat-nr2b9c
CN109072242A (zh) * 2016-02-23 2018-12-21 科罗拉多州立大学董事会法人团体 用于治疗神经损伤的基于肽的方法
US11229675B2 (en) * 2016-04-27 2022-01-25 Biocells (Beijing) Biotech Co., Ltd. Therapeutic peptides for excitatory neurotoxicity-related injuries
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
CN112679595B (zh) * 2020-04-10 2022-11-01 南京市儿童医院 脑源肽或融合肽在新生儿缺氧缺血性脑损伤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425540B2 (en) * 2004-03-30 2008-09-16 The Hospital For Sick Children Method for modification of NMDA receptors through inhibition of Src

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281129T3 (es) * 1997-08-12 2007-09-16 Bristol-Myers Squibb Company Canales de potasio kcnq y procedimientos para su modulacion.
CA2368229A1 (en) * 1999-03-19 2000-09-28 Craig A. Rosen 50 human secreted proteins
NZ527302A (en) * 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
AU2003262642B2 (en) * 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP1551424B1 (en) * 2002-09-04 2015-07-01 Arrowhead Research Corporation Treatment of chronic neuropathic pain by admistration of dsrna
US8003609B2 (en) * 2004-03-30 2011-08-23 The Hospital For Sick Children Method for ameliorating pain by modification of NMDA receptors through inhibition of Src
EP1912680B1 (en) * 2005-06-15 2014-11-26 The Ohio State University Research Foundation Her-2 peptides
ES2446292T3 (es) * 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425540B2 (en) * 2004-03-30 2008-09-16 The Hospital For Sick Children Method for modification of NMDA receptors through inhibition of Src

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
UniProt accession Q36734, 1 November 2006 *
UniProt accession Q7GHE2, 5 July 2004 *

Also Published As

Publication number Publication date
WO2012050921A2 (en) 2012-04-19
CA2812948A1 (en) 2012-04-19
MX2013003330A (es) 2013-09-26
JP2014505655A (ja) 2014-03-06
IL225464A0 (en) 2013-06-27
CN103282379A (zh) 2013-09-04
MX343366B (es) 2016-11-01
UA114592C2 (uk) 2017-07-10
SG189104A1 (en) 2013-05-31
DK2621945T3 (en) 2018-05-22
RU2013119830A (ru) 2014-11-10
US20140274906A1 (en) 2014-09-18
US9073976B2 (en) 2015-07-07
AU2011314074A1 (en) 2013-05-09
CA2812948C (en) 2019-01-22
CN103282379B (zh) 2016-01-06
KR101893473B1 (ko) 2018-08-30
EP2621945B1 (en) 2018-04-11
RU2607033C2 (ru) 2017-01-10
KR20140048070A (ko) 2014-04-23
IL225464B (en) 2018-03-29
BR112013007557A2 (pt) 2021-05-11
JP6073230B2 (ja) 2017-02-01
EP2621945A2 (en) 2013-08-07
WO2012050921A3 (en) 2012-07-05
EP2621945A4 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
AU2010259986B2 (en) Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
JP2019501210A (ja) 神経細胞の損失予防及び再生の効能を有するペプチド及びこれを含む組成物
US9073976B2 (en) ND2 peptides and methods of treating neurological disease
US20250255939A1 (en) Methods and compositions for inducing neural plasticity
JP5336384B2 (ja) Ｍｎｔｆペプチドおよびその類似体を用いて神経細胞障害を治療する方法
HK1187931A (en) Nd2 peptides and methods of treating neurological disease
HK1187931B (en) Nd2 peptides and methods of treating neurological disease
US9402875B2 (en) Amidated dopamine neuron stimulating peptide restoration of mitochondrial activity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired